[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-arrhythmias-and-cardiac-arrest\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-arrhythmias-and-cardiac-arrest":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,69,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100636478","phase-2-using-mirabegron-to-control-arrhythmia-1-100636478",false,"NCT07566208","Using Mirabegron to Control Arrhythmia-1","MACH-1","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, an individual must meet all the following criteria:\n\n  1. Provision of signed and dated informed consent form.\n  2. Age \\> 18 years old.\n  3. Documented VT on ICD.\n\n     1. with \\> 2 episodes of VT per month (on average) over the past 2 months.\n     2. despite guideline-recommended medical therapy (GRMT).\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Patients who are pacemaker-dependent because the pacing artifacts will complicate skin sympathetic nerve activity (SKNA) analysis.\n  2. Clinically unstable (for example, acute myocardial infarction, decompensated heart failure, undergoing cancer chemotherapy, and other acute illness requiring hospitalization)\n  3. Uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both)25\n  4. Active thyrotoxicosis\n  5. Any experimental medication concomitantly or within 4 weeks of participation in the study\n  6. Currently participating in a different clinical trial\n  7. Severe renal impairment (CrCl \\\u003C 30 ml\u002Fmin)\n  8. Hepatic disease (Child-Pugh Class C)\n  9. Pregnant\n  10. Breastfeeding\n  11. Cannot speak, write, and answer questions in English\n  12. Does not have the capacity to consent\n  13. Severe renal impairment (CrCl \\\u003C 30 ml\u002Fmin)\n  14. Hepatic disease (Child-Pugh Class C)\n  15. Pregnant\n  16. Breastfeeding\n  17. Cannot speak, write, and answer questions in English\n  18. Does not have the capacity to consent\n  19. Patients who are known to be allergic to mirabegron or skin patch electrodes\n  20. Patients taking codeine, oxycodone, thioridazine, flecainide, propafenone, and digoxin. (see explanation below)","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","To evaluate mirabegron's effect on ventricular arrhythmia control. The study will be conducted in ambulatory patients with ventricular tachycardia (VT), organic heart diseases, and an implantable cardioverter-defibrillator (ICD). The investigators will perform a pilot study involving 20 patients. Each will receive 50 mg of mirabegron. All will have neuECG recordings made before and 2 months after mirabegron. The data will be analyzed to test the proposed hypothesis.",[26],"Ventricular Arrhythmias and Cardiac Arrest",[28,29,30,31],"mirabegron","Ventricular tachycardia","Ventricular fibrillation","ICD","NOT_YET_RECRUITING","2026-05-04",{"date":35,"type":36},"2026-05-06","ACTUAL",{"date":38,"type":20},"2026-05",{"date":40,"type":20},"2028-05",{"name":42,"class":43},"Cedars-Sinai Medical Center","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100580299","phase-3-prophylactic-anti-arrhythmic-therapy-with-amiodarone-in-critically-ill-patients-admitted-for-an-out-of-hospital-cardiac-arrest-with-initial-shockable-rhythm-100580299","NCT06835491","Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm","Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm.","PARACA","Inclusion Criteria:\n\n1. Patient aged ≥ 18 years\n2. Admitted in intensive care unit\n3. Out-of-hospital cardiac arrest with initial shockable rhythm\n4. Presumed cardiac or unknown cause\n5. Delay between ROSC and screening for randomisation \\\u003C 6 hours\n6. Informed consent from the patient or a surrogate or deferred consent\n7. Affiliated to or benefiting from a social insurance\n\nExclusion Criteria:\n\n1. Cardiac arrest secondary to an extra-cardiac cause (suspected or confirmed)\n2. Indication for amiodarone decided by the physician at ICU admission\n3. No central venous catheter available for continuous infusion of amidoarone\n4. Thyroid disease under treatment\n5. History of cardiac conduction disorders, not treated by permanent pacemaker\n6. Any contra indication to amiodarone treatment\n7. Refractory ventricular arrhythmia or electrical storm\n8. Need for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) at admission\n9. Known limitations in therapy and Do Not Resuscitate-order\n10. Moribund patient due to pre-arrest history (estimated life expectancy \\\u003C 3 months)\n11. Pregnant or breastfeeding women\n12. Patient needing a nadolol treatment due to QT long syndrome or catecholaminergic polymorphic ventricular tachycardia\n13. Patient with known pulmonary fibrosis\n14. Patient with known interstitial lung disease",{"count":53,"type":20},674,[55],"PHASE3","To determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an OHCA with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-cause mortality and\u002For severe in-hospital ventricular arrhythmia recurrence (ventricular fibrillation and\u002For ventricular tachycardia requiring intervention including re-arrest)",[26],"RECRUITING","2025-12-17",{"date":61,"type":36},"2025-12-23",{"date":63,"type":36},"2025-11-06",{"date":65,"type":20},"2027-03-15",{"name":67,"class":43},"Versailles Hospital",29,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100488678","implanted-loop-recorders-for-detection-and-management-of-arrhythmia-with-bruton-tyrosine-kinase-inhibitors-100488678","NCT05643235","Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors","Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors","Inclusion Criteria:\n\n* \\>18yo\n* Willing to sign and date consent form,\n* Willing to be remotely monitored\n* Initiating BTK inhibitor for approved condition (i.e. CLL, Waldenstrom's, etc)\n* Willing to have Medtronic cardiac monitor inserted to allow at minimum 24 hours continuous monitoring prior to initiating BTK inhibitor\n\nExclusion Criteria:\n\n* Documented AF\u002FVA in past 12 months\n* Cerebral Vascular Accident (CVA) or Transient Ischemic Attack (TIA) in past year\n* Has current implanted pulse generator, defibrillator, pacemaker, or resynchronization device\n* heart surgery within past 90 days\n* Myocardial Infarction within past 90 days\n* Patient is taking an anti-arrhythmic or anticoagulant\n* has concomitant condition that precludes safe participation in study (substance abuse, etc)\n* Enrollment in separate study that could confound results of this study",{"count":77,"type":20},50,[79],"NA","This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.",[82,83,26,84,85],"Atrial Fibrillation","Supraventricular Arrhythmia","Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[87,88,89,90,91,92,93,94,95,96,97,98],"Bruton tyrosine kinase (BTK)","Chronic Lymphocytic Leukemia (CLL)","Mantle Cell Lymphoma","Waldenstrom's macroglobulinemia","atrial fibrillation (AF)","ventricular arrhythmia (VA)","sudden cardiac death","ibrutinib","acalabrutinib","zanubrutinib","pirtobrutinib","Implanted Loop Recorder\u002FImplanted Cardiac Monitor (ILR)","2025-09-12",{"date":101,"type":36},"2025-09-18",{"date":103,"type":36},"2023-01-01",{"date":105,"type":20},"2030-12-01",{"name":107,"class":43},"Northwell Health",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":108},"100487794","phase-3-effect-and-safety-of-flecainide-and-metoprolol-versus-metoprolol-alone-to-suppress-ventricular-arrhythmias-in-arrhythmic-mitral-valve-prolapse-100487794","NCT05631730","Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse","An Investigator-Initiated Prospective Randomized Open-Label Blinded-Endpoint Crossover Trial Comparing the Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse","FLECAPRO","Inclusion Criteria:\n\n* Participants must be 18 years of age or older at the time of signing the informed consent.\n* Participants must have mitral valve prolapse evident by echocardiography or cardiac magnetic resonance imaging, defined as more than or equal to 2 mm atrial displacement of any part of the mitral leaflets.\n* Participants must have ventricular arrhythmias, defined as at least one of the following (i) premature ventricular complex burden ≥3% per 24 hours by Holter monitoring, (ii) premature ventricular complex burden ≥1% per 24 hours if multifocal or occurring in bi-\u002Ftrigemini and\u002For couplets by Holter monitoring, (iii) sustained or non-sustained ventricular tachycardia, (iv) aborted cardiac arrest.\n* Participants must have a clinical indication for antiarrhythmic treatment due to ventricular arrhythmias.\n* Participants must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).\n* Participants (only women of childbearing) must accede to mandatory use of a contraceptive method for the duration of the trial and until 3 days after discontinuation of study medication.\n\nExclusion Criteria:\n\n* Strict contraindications to flecainide or metoprolol use\n* Heart failure (signs or symptoms, elevated N-terminal proBNP)\n* Abnormal liver or kidney function (Aspartate aminotransferase (AST)\u002FAlanine aminotransferase (ALT) three times upper normal, estimated glomerular filtration (eGRF) \\\u003C60)\n* Prior myocardial infarction or ischemic heart disease\n* Ion channelopathy, including Brugada syndrome and long QT syndrome\n* Genetic cardiomyopathy (hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, dilated cardiomyopathy, including genotype positive phenotype negative individuals)\n* Atrial flutter or permanent atrial fibrillation\n* Sinus node dysfunction\n* Ongoing electrolyte disorders\n* More than moderate valvular disease according to international guidelines\n* Pre-excitation\n* Any degree of AV-block, except due to enhanced vagal tone (e.g. Wenckebach-block at night in young athletes or 1st-degree AV block that disappears during exercise)\n* Bundle branch block (QRS duration \\>120 ms) or intraventricular conduction defect with QRS \\>120 ms.\n* Prior flecainide therapy.\n* Concomitant use of the following medications (i) CYP2D6 inhibitors\u002Finducers, (ii) class I, III or IV antiarrhythmic drugs, (iii) clozapine, quinidine, cimetidine, bupropion, or (iii) monoamineoxidase (MAO) inhibitors\n* Pregnancy\n* Not willing to use a mandatory contraceptive method for the duration of the trial.",{"count":77,"type":20},[55],"FLECAPRO is a randomized controlled crossover trial assessing the effect and safety of adding flecainide to standard beta-blocker therapy to reduce the burden of ventricular arrhythmias in patients with arrhythmic mitral valve prolapse. The primary endpoint of will be assessed using an implantable loop recorder with blinded endpoint adjudication.",[121,26],"Mitral Valve Prolapse",[123,124,125],"arrhythmic mitral valve prolapse","mitral annular disjunction","ventricular arrhythmia","2025-07-29",{"date":128,"type":36},"2025-07-30",{"date":130,"type":36},"2023-01-04",{"date":132,"type":20},"2026-06",{"name":134,"class":43},"Oslo University Hospital"]